Your Medications Aren't Working. Your Genes May Be Metabolizing Them Too Fast.

CYP2D6 is your liver’s workhorse for breaking down antidepressants, pain medications, and heart drugs. It sits in your hepatic cells and converts these medications into inactive forms that your body can eliminate. When this enzyme works normally, drugs reach their therapeutic peak and then clear appropriately. This gene has been fine-tuned by evolution to handle the medications that your ancestors needed.

But CYP2D6 is duplicated in roughly 1-3% of people, and these individuals are rapid metabolizers. They carry extra copies of the gene, meaning their livers churn out extra enzyme. When you take a standard antidepressant dose, your CYP2D6 may metabolize it so quickly that you experience no therapeutic benefit whatsoever. You feel the same fog, the same sadness, the same anxiety as before you started the medication.

From your perspective, the medication simply did not work. From your doctor’s perspective, you may be treatment-resistant. But from your genetics perspective, the dose was never high enough in your bloodstream to do anything. You needed either a higher dose, a drug metabolized by a different enzyme, or a different approach entirely.

CYP2C19 is the enzyme responsible for activating clopidogrel, the anti-clotting medication prescribed after stents or heart attacks. It also metabolizes many SSRIs and PPIs (proton pump inhibitors for acid reflux). This enzyme is essential for converting prodrugs into their active forms. When it works normally, clopidogrel is activated and protects your blood vessels.

But roughly 30-40% of East Asian populations and 2-15% of European populations carry loss-of-function variants in CYP2C19. If you’re a rapid metabolizer of CYP2C19, you activate clopidogrel almost instantaneously, then deactivate it just as quickly. The protective window of platelet inhibition shrinks dramatically. Your cardiologist prescribed the standard dose thinking you’d be protected. You are not.

For antidepressants metabolized by CYP2C19, the effect is the opposite: you clear them so fast that standard doses feel ineffective. You feel like the medication did nothing. You blame the drug. Your doctor blames your biology. But the real issue is that your rapid metabolism rendered the standard dose subtherapeutic from day one.

CYP2C9 metabolizes warfarin, the blood thinner used to prevent stroke in people with atrial fibrillation. It also breaks down NSAIDs like ibuprofen and meloxicam, and helps clear certain statins. This enzyme is critical for maintaining the balance between bleeding risk and clotting risk. When it works normally, warfarin reaches a therapeutic dose that prevents clots without causing hemorrhage.

Roughly 5-10% of people of European ancestry carry CYP2C9 variants that impair this enzyme’s function. But rapid metabolizers, though less common, exist at the other end of the spectrum. If you rapidly metabolize CYP2C9 substrates, your body clears warfarin or NSAIDs so quickly that standard doses become sub-therapeutic. Your INR (the measure of blood thinning) stays low despite the dose your cardiologist prescribed. Your clot risk remains elevated. Or if you’re taking NSAIDs for arthritis, the pain relief never materializes because the drug is already being cleared.

Your doctor sees the lab values and assumes you’re non-compliant or that you need a higher dose. But the real issue is that your rapid metabolism is working against the medication’s intended effect.

SLCO1B1 encodes a transporter protein that brings statins into your liver cells, where they do their job of lowering cholesterol. This is not an enzyme that metabolizes the statin. It is a gatekeeper that controls how much statin actually enters the organ where it works. Without adequate SLCO1B1 function, statins accumulate in your bloodstream instead of concentrating in your liver.

The SLCO1B1 *5 variant, carried by roughly 15% of European ancestry populations, reduces this transporter’s efficiency. If you carry this variant, statins cannot enter your liver effectively, which means they linger in your blood and accumulate in your muscles. This dramatically increases your risk of statin-induced muscle pain, weakness, and rhabdomyolysis. Conversely, rapid metabolizers of the statin itself may need higher doses because less of the drug is reaching the target organ.

Your doctor prescribed a standard statin dose and told you it was safe. Your liver function tests look normal. But your muscles ache, your energy is gone, and the statin dose is actually dangerous for your specific biology. You blame the medication class. Your doctor runs more tests. But the real issue is that your SLCO1B1 transporter is allowing statins to accumulate where they cause harm, not where they help.

VKORC1 encodes the enzyme that recycles vitamin K. This may sound unrelated to warfarin, but warfarin works by inhibiting VKORC1. The more efficient your VKORC1, the more sensitive you are to warfarin’s effects. This gene is one of the strongest predictors of warfarin dose variation in the entire genome. Some people need 2 mg per day. Others need 10 mg per day. The difference is not poor compliance. It is encoded in VKORC1.

Roughly 40% of people of European ancestry carry the A allele of the VKORC1 -1639G>A variant. If you carry this allele, your VKORC1 is highly sensitive to warfarin inhibition, meaning standard doses of warfarin may cause excessive bleeding. But the opposite can also be true: if you have fast VKORC1 recycling, you are resistant to warfarin and need much higher doses to achieve anticoagulation. Your doctor prescribed 5 mg per day based on population averages. But your VKORC1 status may require 3 mg or 8 mg. Only your genes know which one is safe.

Your INR tests come back unpredictable. Your doctor keeps adjusting. But the real reason your warfarin response is erratic is not your biology gone wrong. It is your VKORC1 sensitivity determining how much warfarin you actually need.

MTHFR converts folate into its active form, 5-methyltetrahydrofolate, which is essential for dozens of biochemical reactions including DNA synthesis and methylation. This gene is also involved in processing certain medications, particularly methotrexate, a drug used for autoimmune diseases and cancer. When MTHFR works normally, your cells have adequate active folate and medications are metabolized appropriately.

Roughly 40% of people of European ancestry carry the C677T variant in MTHFR, which reduces enzyme function by 35-40%. If you have this variant, your folate-dependent pathways are compromised, which impairs your metabolism of methotrexate and other folate-pathway drugs. Your rheumatologist prescribed methotrexate for your rheumatoid arthritis. Standard doses have worked for most of her patients. But your body is not converting folate efficiently, so methotrexate accumulates or is not processed as expected. You experience more side effects than usual, or the drug fails to work despite adequate dosing.

Your doctor assumes you need a different medication. But the real issue is that your MTHFR variant is preventing your cells from handling this drug at standard doses. You may need folinic acid supplementation, dose adjustment, or a different drug class entirely.